| Adlyxin (lixisenatide) / Sanofi |
RESTORE, NCT00931372: Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2 |
|
|
| Completed | 1 | 22 | Europe | Lixisenatide (AVE0010), Placebo | Sanofi, Profil GmbH, Neuss, Germany | Diabetes Mellitus, Type 2 | 08/09 | 08/09 | | |
NCT01146678: Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1 |
|
|
| Completed | 1 | 22 | Europe | Insulin glargine HOE901, Lixisenatide AVE0010 | Sanofi | Type 1 Diabetes Mellitus | 09/10 | 01/11 | | |
NCT01572649 / 2011-004584-67: Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes |
|
|
| Completed | 1 | 24 | US, Europe, RoW | Lixisenatide (AVE0010), Placebo | Sanofi | Type 2 Diabetes Mellitus | 03/14 | 03/14 | | |
NCT02231658: Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion |
|
|
| Terminated | 1 | 109 | Europe | Liraglutide, Lixisenatide | Profil Institut für Stoffwechselforschung GmbH | Diabetes Mellitus | 07/18 | 07/18 | | |
